Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years, male or female. * ECOG performance status 0-2. * Expected survival ≥ 3 months. * Histologically or cytologically confirmed advanced solid malignancies: * Cohort A: Advanced NSCLC with negative driver genes (EGFR/ALK/ROS1), disease progression during first-line platinum-based doublet chemotherapy combined with PD-1/PD-L1 inhibitors. * Cohort B: Advanced NSCLC with positive driver genes (EGFR/ALK/ROS1), disease progression during first-line targeted therapy. * Cohort C: Advanced colorectal or pancreatic cancer, disease progression during no more than two lines of therapy. * Confirmed liver metastasis (pathologically or by 2 imaging modalities). * At least 1 measurable intrahepatic target lesion per RECIST v1.1. * Brain metastases are permitted if radiologically stable. * Adequate major organ function within 7 days prior to enrollment: * Hematology: Absolute neutrophil count ≥ 1.5 × 10\^9/L, Platelets ≥ 100 × 10\^9/L, Hemoglobin ≥ 90 g/L. * Liver: Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome or liver metastasis); AST/ALT ≤ 2.5 × ULN (≤ 5 × ULN for liver metastasis). * Kidney: Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula). Exclusion Criteria: * Contraindications to radiotherapy and immune checkpoint inhibitor therapy. * Prior unacceptable toxicity following immune checkpoint inhibitor therapy. * History of abdominopelvic radiotherapy within 6 months prior to enrollment. * Prior anti-tumor adverse events not recovered to CTCAE 5.0 Grade ≤ 1. * Active uncontrolled systemic bacterial, viral, or fungal infection. * Use of antibiotics, antifungals, antivirals, or antiparasitics within 2 weeks prior to enrollment. * Any lesion burden with a maximum diameter \> 4 cm. * Other standard exclusion criteria (e.g., pregnancy, lactation, severe comorbidities, etc.).